Product Center
IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-30
- Views:
(Summary description)Recently, the IND application for a class I new drug "Quadrivalent Influenza Virus Subunit Vaccine (Adjuvant)" jointly submitted by Ab&B Bio-Tech Co., Ltd (Ab&B Bio-Tech Co., Ltd) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration.
IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved
(Summary description)Recently, the IND application for a class I new drug "Quadrivalent Influenza Virus Subunit Vaccine (Adjuvant)" jointly submitted by Ab&B Bio-Tech Co., Ltd (Ab&B Bio-Tech Co., Ltd) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-07-30 11:57
- Views:
Recently, the IND application for a class I new drug "Quadrivalent Influenza Virus Subunit Vaccine (Adjuvant)" jointly submitted by Ab&B Bio-Tech Co., Ltd (Ab&B Bio-Tech Co., Ltd) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Drug Administration.
Source: Website of the Center for Drug Evaluation of the State Drug Administration
At present, influenza virus is still one of the important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of influenza viruses have a significant impact on human health and social economy. Compared with other age groups, the infection rate of the elderly is higher, and the risk of severe illness and death after contracting influenza is greater, and this risk increases with age. WHO and the Chinese Center for Disease Control and Prevention recommend that the elderly be one of the priority groups for influenza vaccination.
The "quadrivalent influenza virus subunit vaccine (adjuvant)" accepted this time is the first adjuvanted influenza vaccine in China to protect the elderly aged 65 and above from four seasonal influenza virus strains. It uses the company's independently innovated subunit influenza antigens and new adjuvants; preclinical studies have shown that the vaccine can significantly increase the body's antibody level and neutralizing antibody titer, and has significant advantages in improving immune response capabilities.
On July 29, Ab&B Bio-Tech Co., Ltd (Ab&B Bio-Tech Co., Ltd) and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly submitted another Class I new drug trivalent "Influenza virus subunit vaccine (adjuvant)" IND application, which was also accepted by the Center for Drug Evaluation (CDE) of the China National Drug Administration. This marks that the company's influenza virus vaccine family is growing, and the coverage and selection range are becoming more comprehensive.
Source: Website of the Center for Drug Evaluation of the State Drug Administration
Relevant information
-
Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvantsOn August 25th, the R&D team of Yither Biotech (Shanghai) Co., Ltd, a wholly-owned subsidiary of Ab&B Bio Tech Co., Ltd (locally referred to as "Zhonghui Bio"), made a breakthrough in the field of innovative adjuvant research and development. The research results were published online in the internationally renowned journal "Journal of Drug Delivery Science and Technology" under the title "Dual functional Emulsifier Based Nano Emulsification Adjuvant Effectively Enhanced Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine in Mice". - Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
- IND application for quadrivalent influenza virus subunit vaccine (adjuvant) approved 07-30
- World Influenza Conference 2024 | Decoding new possibilities for the future of influenza vaccines 07-09
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
